Molecules with reduced effector function and extended half-lives, compositions, and uses thereof
Provided are polypeptides comprising a variant IgG Fc domain, wherein the polypeptides exhibit reduced or ablated effector functions (e.g., ADCC and/or CDC) and increased stability and plasma half-life compared to a parent polypeptide. Also provided are compositions, methods of treatment, and methods to diminish Fc-induced effector function in a parent polypeptide.
1. An isolated polypeptide comprising a human immunoglobulin G class 1 (IgG 1 ) Fc domain, wherein the IgG 1 Fc domain comprises:
(a) a Phenylalanine (F) amino acid at position 234;
(b) a Glutamine (Q) at position 235; and,
(c) a Glutamine (Q) amino acid at position 322,
wherein the amino acid numbering is according to the EU index as in Kabat.
2. The polypeptide of claim 1 , further comprising a Glycine (G) amino acid at position 331, wherein the amino acid numbering is according to the EU index as in Kabat.
3. The polypeptide of claim 1 , further comprising:
(a) a Tyrosine (Y) amino acid at position 252, or a Serine (S) amino acid at position 252, or a Tryptophan (W) amino acid at position 252 or a Threonine (T) amino acid at position 252; and/or
(b) a Threonine (T) amino acid at position 254; and/or
(c) a Glutamic acid (E) amino acid at position 256, or a Serine (S) amino acid at position 256, or a Arginine (R) amino acid at position 256, or a Glutamine (Q) amino acid at position 256, or an Aspartate (D) amino acid at position 256,
wherein the amino acid numbering is according to the EU index as in Kabat.
4. The polypeptide of claim 1 , further comprising:
(a) a Tyrosine (Y) amino acid at position 252; and/or
(b) a Threonine (T) amino acid at position 254; and/or
(c) a Glutamic acid (E) amino acid at position 256,
wherein the amino acid numbering is according to the EU index as in Kabat.
5. The polypeptide of claim 1 , further comprising:
(a) a Tyrosine (Y)amino acid at position 252 or a Threonine (T) amino acid at position 252; and
(b) a Threonine (T) amino acid at position 254,
wherein the amino acid numbering is according to the EU index as in Kabat.
6. The polypeptide of claim 1 , further comprising:
(a) a Threonine (T) amino acid at position 254; and
(b) a Glutamic acid (E) amino acid at position 256, or a Serine (S) amino acid at position 256, or a Arginine (R) amino acid at position 256, or a Glutamine (Q) amino acid at position 256, or an Aspartate (D) amino acid at position 256,
wherein the amino acid numbering is according to the EU index as in Kabat.
7. The polypeptide of claim 1 , further comprising:
(a) a Tyrosine (Y) amino acid at position 252, or a Serine (S) amino acid at position 252, or a Tryptophan (W) amino acid at position 252 or a Threonine (T) amino acid at position 252; and
(b) a Glutamic acid (E) amino acid at position 256, or a Serine (S) amino acid at position 256, or a Arginine (R) amino acid at position 256, or a Glutamine (Q) amino acid at position 256, or an Aspartate (D) amino acid at position 256,
wherein the amino acid numbering is according to the EU index as in Kabat.
8. The polypeptide of claim 1 , further comprising:
(a) a Tyrosine (Y) amino acid at position 252, and a Threonine (T) amino acid at position 254; or,
(b) a Threonine (T) amino acid at position 254 and a Glutamic acid (E) amino acid at position 256; or,
(c) a Tyrosine (Y) amino acid at position 252 and a Glutamic acid (E) amino acid at position 256
wherein the amino acid numbering is according to the EU index as in Kabat.
9. The polypeptide of claim 1 , further comprising a Tyrosine (Y) amino acid at position 252, a Threonine (T) amino acid at position 254, and, a Glutamic acid (E) amino acid at position 256, wherein the amino acid numbering is according to the EU index as in Kabat.
10. The polypeptide of claim 1 , comprising:
(a) a Phenylalanine (F) amino acid at position 234;
(b) a Glutamine (Q) amino acid at position 235;
(c) a Glutamine (Q) amino acid at position 322;
(d) a Tyrosine (Y) amino acid at position 252;
(e) a Threonine (T) amino acid at position 254; and,
(f) a Glutamic acid (E) amino acid at position 256,
wherein the amino acid numbering is according to the EU index as in Kabat.
11. The polypeptide of claim 1 , further comprising:
(a) a Glycine (G) amino acid at position 331;
(b) a Tyrosine (Y) amino acid at position 252;
(c) a Threonine (T) amino acid at position 254; and,
(d) a Glutamic acid (E) amino acid at position 256,
wherein the amino acid numbering is according to the EU index as in Kabat.
12. The polypeptide of claim 1 , wherein the polypeptide has an improved pharmacokinetic (PK) property when compared to the same polypeptide comprising a wild-type IgG 1 Fc domain.
13. The polypeptide of claim 12 , wherein the PK property is half-life.
14. The polypeptide of claim 1 , wherein the polypeptide has improved FcRn binding when compared to the same polypeptide comprising a wild-type IgG 1 Fc domain.
15. The polypeptide of claim 1 , wherein the polypeptide further comprises an antigen binding domain.
16. The polypeptide of claim 15 , wherein the antigen-binding domain is derived from a monoclonal antibody or an antigen-binding fragment thereof.
17. The polypeptide of claim 15 , wherein the antigen-binding domain is derived from a human antibody, a humanized antibody, or a chimeric antibody.
18. The polypeptide of claim 15 , wherein the antigen-binding domain comprises:
(a) a single chain antibody;
(b) a diabody;
(c) a polypeptide chain of an antibody;
(d) an F(ab′) 2 fragment; or,
(e) and F(ab) fragment.
19. The polypeptide of claim 1 , wherein the polypeptide has reduced Fc-mediated effector function when compared to the same polypeptide comprising a wild-type IgG 1 Fc domain.
20. The polypeptide of claim 19 , wherein the effector function is antibody-dependent cell-mediated cytotoxicity (ADCC).
21. The polypeptide of claim 19 , wherein the effector function is complement-dependent cytotoxicity (CDC).
22. The polypeptide of claim 1 , wherein the polypeptide has lower affinity for an Fc gamma receptor (FcγR) when compared to the same polypeptide comprising a wild-type IgG 1 Fc domain.
23. The polypeptide of claim 22 , wherein the FcγR is a human FcγR.
24. The polypeptide of claim 22 , wherein the FcγR is selected from the group consisting of FcγRI, FcγRII, and FcγRIII.
25. The polypeptide of claim 24 , wherein the FcγRI is FcγRIa.
26. The polypeptide of claim 24 , wherein the FcγRII is FcγRIIa or FcγRIIb.
27. The polypeptide of claim 24 , wherein the FcγRIII is FcγRIII (158V) or FcγRIII (158F).
28. The polypeptide of claim 1 , wherein the polypeptide binds with improved affinity to FcRn when compared to the same polypeptide comprising a wild-type IgG 1 Fc domain.
29. The polypeptide of claim 28 , wherein the polypeptide has a higher affinity for FcRn at pH 6.0 than at pH 7.4.
30. The polypeptide of claim 1 , wherein the polypeptide binds with reduced affinity to C1q when compared to the same polypeptide comprising a wild-type IgG 1 Fc domain.
31. The polypeptide of claim 1 , wherein the polypeptide displays an increase in thermal stability when compared to the same polypeptide comprising a Phenylalanine-Glutamic acid-Serine (FES)-YTE IgG 1 Fc domain.
32. The polypeptide of claim 31 , wherein thermal stability is measured by Differential Scanning Calorimetry (DSC).
33. The polypeptide of claim 32 , wherein the increase in thermal stability is at least 4° C.
34. The polypeptide of claim 31 , wherein thermal stability is measured by Differential Scanning Fluorimetry (DSF).
35. The polypeptide of claim 34 , wherein the DSF fluorescent probe is Sypro Orange.
36. The polypeptide of claim 35 , wherein the increase in thermal stability increases is at least 5° C.
37. The polypeptide of claim 1 , wherein the polypeptide displays an increase in apparent solubility as measured using a polyethylene glycol (PEG) precipitation assay when compared to the same polypeptide comprising a Phenylalanine-Glutamic acid-Serine (FES)-YTE IgG 1 Fc domain.
38. The polypeptide of claim 1 , wherein the polypeptide displays an increase in stability as measured using an accelerated stability assay when compared to the same polypeptide comprising a Phenylalanine-Glutamic acid-Serine (FES)-YTE IgG 1 Fc domain.
39. The polypeptide of claim 38 , wherein the accelerated stability assay comprises: (i) incubation of the polypeptide for an extended time period, and (ii) incubation at high temperature.
40. The polypeptide of claim 39 , wherein the accelerated stability assay is performed by incubation at a high concentration.
41. The polypeptide of claim 39 , wherein the extended time period is at least one month.
42. The polypeptide of claim 40 , wherein the high concentration is at least 25 mg/ml.
43. The polypeptide of claim 39 , wherein the high temperature is at least 40° C.
44. The polypeptide of claim 38 , wherein the accelerated stability assay is performed using High Performance Size Exclusion Chromatography (HPSEC) or Dynamic Light Scattering (DLS).
45. A composition comprising the polypeptide according to claim 1 and a carrier.
46. A conjugate comprising the polypeptide according to claim 1 and a therapeutic moiety.
47. A kit comprising the polypeptide according to claim 1 , or the composition of claim 45 .